Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

RHYTHM PHARMACEUTICALS, INC. (RYTM)

$89.47 +0.22% NASDAQ: RYTM · 15-min delayed
  • BOSTON, Massachusetts
  • Public · NASDAQ: RYTM
  • 414 employees
  • Founded 2008
$7.0BMarket cap
$189.8MRevenue · FY2025
-$196.5MNet income
414Employees
RYTMNASDAQ
2017IPO

About RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2025
$189.8M
Net income
-$196.5M
Total assets
$480.2M
Market cap
$7.0B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: RYTM
$89.47 +0.22%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$75.82 $117.62

52-week range

Market cap
$7.0B
Shares outstanding
78.3M
Open
—
Day range
–
Prev close
—
Volume
—
IPO date
Oct 5, 2017

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price

  • Reported a net loss of $196.5M in FY2025.
  • Trading 24% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review RHYTHM PHARMACEUTICALS, INC..

Write a review
Newsroom

News about RHYTHM PHARMACEUTICALS, INC.

News & sentiment via Polygon.io

FAQ

Rhythm Pharmaceuticals, Inc.: frequently asked questions

Is Rhythm Pharmaceuticals, Inc. an American company?

Rhythm Pharmaceuticals, Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Rhythm Pharmaceuticals, Inc. headquartered?

Rhythm Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts, United States.

Is Rhythm Pharmaceuticals, Inc. publicly traded?

Yes — Rhythm Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol RYTM on the NASDAQ.

What does Rhythm Pharmaceuticals, Inc. do?

Rhythm Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Rhythm Pharmaceuticals, Inc. founded?

Rhythm Pharmaceuticals, Inc. was founded in 2008.

Explore

Similar companies

Browse all →